Bicycle Therapeutics: Pay

Bicycle Therapeutics paid its 3 named executives $11.0M in total in FY2025 (Dec). CEO Kevin Lee, Ph.D., MBA was paid $6.3M of that.

Pay$100 in the stock at the end of FY21 → $19
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Kevin Lee, Ph.D., MBAChief Executive Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2022 (Dec)Not disclosed
3 years
Michael Skynner, Ph.D.Chief Scientific Officer
FY2025 (Dec)
1 year
Alistair MilnesChief Corporate Development Officer
FY2025 (Dec)Not disclosed
FY2024 (Dec)
FY2023 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
4 years

CEO pay against the pay peers

In FY2024 (Dec), the median CEO pay of the 8 peers with pay on file was $10.0M. The CEO of Bicycle Therapeutics was paid $4.9M, 51% below the median.

  1. 1TG Therapeutics
  2. 2Ionis Pharmaceuticals
  3. 3Intellia Therapeutics
  4. 4Arvinas
  5. 5Arcus Biosciences
  6. 6Agios Pharmaceuticals
  7. 7Beam Therapeutics
  8. 8Cogent Biosciences
  9. 9Bicycle Therapeutics
  10. 10Blueprint Medicines CorporationNot disclosed
  11. 11Deciphera Pharmaceuticals, Inc.Not disclosed
  12. 12ImmunoGen, Inc.Not disclosed
  13. 13Karuna Therapeutics, Inc.Not disclosed
  14. 14Revance Therapeutics, Inc.Not disclosed
  15. 15Rhythm PharmaceuticalsNot disclosed
  16. 16Sage Therapeutics, Inc.Not disclosed
  17. 17SpringWorks Therapeutics, Inc.Not disclosed
  18. 18Syndax PharmaceuticalsNot disclosed
  19. 19XencorNot disclosed
  20. 20Zentalis Pharmaceuticals, Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.